Allan T van Oosterom
Overview
Explore the profile of Allan T van Oosterom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dumez H, Martens M, Selleslach J, Guetens G, De Boeck G, Aerts R, et al.
Anticancer Drugs
. 2006 Dec;
18(2):211-8.
PMID: 17159607
Our objective was to determine the response to gemcitabine plus docetaxel in advanced urothelial transitional cell carcinoma in a phase II trial, and gemcitabine distribution between plasma and erythrocytes, following...
12.
Demetri G, van Oosterom A, Garrett C, Blackstein M, Shah M, Verweij J, et al.
Lancet
. 2006 Oct;
368(9544):1329-38.
PMID: 17046465
Background: No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy...
13.
Gardner E, Burger H, van Schaik R, van Oosterom A, De Bruijn E, Guetens G, et al.
Clin Pharmacol Ther
. 2006 Aug;
80(2):192-201.
PMID: 16890580
Objective: Our objective was to explore the relationships between imatinib pharmacokinetics and 9 allelic variants in 7 genes coding for adenosine triphosphate-binding cassette transporters (ABCB1 and ABCG2) and enzymes (cytochrome...
14.
Van Glabbeke M, Verweij J, Casali P, Simes J, Cesne A, Reichardt P, et al.
Eur J Cancer
. 2006 Aug;
42(14):2277-85.
PMID: 16876399
The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to...
15.
Prenen H, Guetens G, De Boeck G, Highley M, van Oosterom A, De Bruijn E
J Pharm Pharmacol
. 2006 Jul;
58(8):1063-6.
PMID: 16872552
The signal transduction inhibitor imatinib is one of the latest breakthroughs in cancer pharmacotherapy. It is administered orally over prolonged periods of time for the treatment of gastro-intestinal stromal tumours....
16.
Debiec-Rychter M, Sciot R, Cesne A, Schlemmer M, Hohenberger P, van Oosterom A, et al.
Eur J Cancer
. 2006 Apr;
42(8):1093-103.
PMID: 16624552
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of...
17.
Guetens G, Prenen H, De Boeck G, Highley M, De Wever I, van Oosterom A, et al.
J Sep Sci
. 2006 Mar;
29(3):453-9.
PMID: 16544888
The analysis of the signal transduction inhibitor imatinib in patient tumour tissue using LC and MS/MS is described. The anticancer agent is eluted over RP-C18 within 2 mm together with...
18.
Prenen H, Guetens G, De Boeck G, Debiec-Rychter M, Manley P, Schoffski P, et al.
Pharmacology
. 2006 Mar;
77(1):11-6.
PMID: 16534250
Imatinib and AMN107 are protein tyrosine kinase inhibitors which reduce KIT autophosphorylation with similar potency. This report describes the cellular uptake of these compounds in two human gastrointestinal stromal tumor...
19.
Heinrich M, McArthur G, Demetri G, Joensuu H, Bono P, Herrmann R, et al.
J Clin Oncol
. 2006 Mar;
24(7):1195-203.
PMID: 16505440
Purpose: To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent. Patients And Methods: Nineteen...
20.
Hoekstra R, Dumez H, Eskens F, van der Gaast A, Planting A, de Heus G, et al.
Clin Cancer Res
. 2005 Oct;
11(19 Pt 1):6908-15.
PMID: 16203782
Purpose: This phase I study was conducted to assess the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor tyrosine kinase inhibitor PKI166 in patients with...